HIGHLIGHTS
- who: Chenglong Liu from the des Cordeliers (CRC), France University of Virginia, United States have published the paper: Clinical cancer immunotherapy: Current progress and prospects, in the Journal: (JOURNAL)
- how: II clinical trial for HER-2-overexpressing or HER-2-mutated NSCLC (NCT03505710) the results showed that the ORR of Enhertu ([fam]-trastuzumab deruxtecan an HER-2 ADC) was 61.9% and the median PFS was 14 months.
- future: Although small-molecule drugs targeting the extracellular or intracellular pathways of adaptive immunity or innate immunity have been developed most of them are in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.